Daniel Bloomfield
Research Subjects
Daniel Bloomfield has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Aditi Sapre
1 shared publicationArthur J. Bergman
Merck & Company Inc, Whitehouse Station, New Jersey
1 shared publicationChristine McCrary Sisk
1 shared publicationD Hreniuk
Department of Clinical Pharmacology, Merck Research Laboratories, Merck and Company, Rahway, New Jersey, USA
1 shared publicationDavid Hreniuk
Merck & Company Inc, Whitehouse Station, New Jersey
1 shared publicationDiane Tribble
1 shared publication
Latest Publications
- 3 April 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (5) , 444-6
Incorporating exposure-response modeling into the assessment of QTc interval: A potential alternative to the thorough QT study.
ICH E14 mandates that a thorough QTc study (TQT) is conducted as part of the clinical drug development program to provide an accurate and precise estimate of a drug's effect on the QTc. In the April issue of CPT, Darpo et al. report the results of a study which validated an alternative approach to evaluating the effect of a drug on QTc using exposure‐response modeling in phase I which has the potential to make the TQT study obsolete.
- 3 April 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (5) , 444-6
Incorporating exposure-response modeling into the assessment of QTc interval: A potential alternative to the thorough QT study.
ICH E14 mandates that a thorough QTc study (TQT) is conducted as part of the clinical drug development program to provide an accurate and precise estimate of a drug's effect on the QTc. In the April issue of CPT, Darpo et al. report the results of a study which validated an alternative approach to evaluating the effect of a drug on QTc using exposure‐response modeling in phase I which has the potential to make the TQT study obsolete.
- 1 August 2009
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (8) , 937-946
A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
A randomized, double‐blind, placebo‐controlled, 4‐period crossover study was performed with a single oral dose of sitagliptin (100 mg, 800 mg), moxifloxacin (400 mg), and placebo in order to provide a rigorous assessment of the effect of sitagliptin on ventricular repolarization based on the ICH E14 guidance. The clinical dose of sitagliptin 100 mg was not associated with an increase in QTc interval, corrected using the Fridericia correction (QTcf), at any time point. The supratherapeutic 800‐mg dose of sitagliptin was generally well tolerated and was associated with minimal, clinically insignificant prolongation of the QTcf interval at concentrations approximately 11‐fold higher than maximal concentrations following the 100‐mg clinical dose. The PK/QTc model demonstrated a shallow relationship between the plasma concentration of sitagliptin and the placebo‐subtracted QTcf change from baseline, with a 0.59‐millisecond increase in QTc for every 1000‐nM increment in sitagliptin plasma concentration. The sensitivity of the assay to detect modest increases in QTc interval was established with the active control moxifloxacin. In conclusion, at clinically relevant concentrations, sitagliptin is not associated with clinically meaningful QTcf prolongation.
- 1 August 2009
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (8) , 937-946
A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
A randomized, double‐blind, placebo‐controlled, 4‐period crossover study was performed with a single oral dose of sitagliptin (100 mg, 800 mg), moxifloxacin (400 mg), and placebo in order to provide a rigorous assessment of the effect of sitagliptin on ventricular repolarization based on the ICH E14 guidance. The clinical dose of sitagliptin 100 mg was not associated with an increase in QTc interval, corrected using the Fridericia correction (QTcf), at any time point. The supratherapeutic 800‐mg dose of sitagliptin was generally well tolerated and was associated with minimal, clinically insignificant prolongation of the QTcf interval at concentrations approximately 11‐fold higher than maximal concentrations following the 100‐mg clinical dose. The PK/QTc model demonstrated a shallow relationship between the plasma concentration of sitagliptin and the placebo‐subtracted QTcf change from baseline, with a 0.59‐millisecond increase in QTc for every 1000‐nM increment in sitagliptin plasma concentration. The sensitivity of the assay to detect modest increases in QTc interval was established with the active control moxifloxacin. In conclusion, at clinically relevant concentrations, sitagliptin is not associated with clinically meaningful QTcf prolongation.
- 1 April 2009
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 85 (4) , 365-366
Evaluating QTc in Patients With Advanced Parkinson's Disease: Overcoming Artifact
Electrocardiograms (ECGs) in patients with Parkinson's disease are affected by artifacts related to muscle tremor. Malik et al. report methods used in QTc study in patients with Parkinson's disease that markedly reduce the noise and variance of QTc in a sample of ECGs that are undeniably difficult to interpret. This study adds significant experience and novel methods that have the potential to further enhance the evaluation of the effect of a drug on QTc.
- 1 April 2009
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 85 (4) , 365-366
Evaluating QTc in Patients With Advanced Parkinson's Disease: Overcoming Artifact
Electrocardiograms (ECGs) in patients with Parkinson's disease are affected by artifacts related to muscle tremor. Malik et al. report methods used in QTc study in patients with Parkinson's disease that markedly reduce the noise and variance of QTc in a sample of ECGs that are undeniably difficult to interpret. This study adds significant experience and novel methods that have the potential to further enhance the evaluation of the effect of a drug on QTc.
- 1 February 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (2) , 352-360.e2
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
- 1 February 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (2) , 352-360.e2
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
- 26 March 2008
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (4) , 475-480
The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies
A number of issues have remained unanswered in the design of “thorough QT” (TQT) studies. In this randomized, placebo‐controlled, two‐period crossover study in 20 healthy subjects, replicate electrocardiograms (ECGs) were recorded on a digital 12‐lead Holter recorder, extracted in a core ECG laboratory, and interpreted manually by a cardiologist. The observed within‐subject variability was slightly greater when time‐matched baselines were employed than when predose baselines were employed, whereas the magnitude of the increase in QTc was similar for both. Moxifloxacin 400 mg was associated with an observed 7.5–12.5 ms increase in the mean placebo‐ and baseline‐corrected QTc interval. A PK‐QTc model estimated a 3.9 ms increase in the QTc interval for every 1,000 ng/ml increase in moxifloxacin concentration. The QTc increases associated with moxifloxacin support the appropriateness of its use as a positive control in TQT studies. This crossover study failed to justify the use of time‐matched baselines rather than the less resource‐intensive predose definition of baseline. Clinical Pharmacology & Therapeutics (2008); 84, 4, 475–480 doi:10.1038/clpt.2008.33
- 26 March 2008
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (4) , 475-480
The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies
A number of issues have remained unanswered in the design of “thorough QT” (TQT) studies. In this randomized, placebo‐controlled, two‐period crossover study in 20 healthy subjects, replicate electrocardiograms (ECGs) were recorded on a digital 12‐lead Holter recorder, extracted in a core ECG laboratory, and interpreted manually by a cardiologist. The observed within‐subject variability was slightly greater when time‐matched baselines were employed than when predose baselines were employed, whereas the magnitude of the increase in QTc was similar for both. Moxifloxacin 400 mg was associated with an observed 7.5–12.5 ms increase in the mean placebo‐ and baseline‐corrected QTc interval. A PK‐QTc model estimated a 3.9 ms increase in the QTc interval for every 1,000 ng/ml increase in moxifloxacin concentration. The QTc increases associated with moxifloxacin support the appropriateness of its use as a positive control in TQT studies. This crossover study failed to justify the use of time‐matched baselines rather than the less resource‐intensive predose definition of baseline. Clinical Pharmacology & Therapeutics (2008); 84, 4, 475–480 doi:10.1038/clpt.2008.33
- 1 January 2008
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (1) , 6-8
Commentary on the Clinical Relevance of Concentration/QTc Relationships for New Drug Candidates
- 1 January 2008
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (1) , 6-8
Commentary on the Clinical Relevance of Concentration/QTc Relationships for New Drug Candidates